Food and Drug Administration granted an emergency authorization PfizerThe Covid pill is a significant milestone in the fight against the virus.

The FDA has approved the FDA’s first antiviral drug that is specifically designed for fighting Covid. This authorization is crucial in light of the current pandemic. Hospital systems in America have already been hit hard by the wave of Delta infections and now face a new wave of infected patients with the contagious Omicron variant.

Covid can now be fought with the new drug. The vaccines are very effective in protecting against severe illnesses from the virus. However, the U.S. health care providers require medication for the many millions who are still not vaccinated. If the pill is given in time, it could reduce strain on healthcare systems as a result of the expected wave of Omicron infection.

U.S. bought 10 million Paxlovid treatments from Pfizer in $5 billion deals. The President Joe Biden indicated in November that his administration would work to ensure the access and affordability of these treatments. Biden last month stated that the delivery of these treatments would commence in 2020 and go on through 2022. CNBC heard from Albert Bourla, Pfizer’s CEO earlier this month that Pfizer has shipped its product to the U.S. already and will make the pills available when the FDA approves.

Merck signed a contract with the U.S. government for at least 3,000,000 units of its pill, molnupiravir. This order was valued at $2.2 billion.

Pfizer gives its treatment in 150 mg tablets and a 100mg tablet of a HIV drug called Ritonavir twice daily. Because the HIV drug slows the patient’s metabolism it allows Paxlovid in their body to stay active for longer periods of time at a greater concentration.

Merck recommends that 800mg pills be taken within 12 hours of symptom onset. This is for five consecutive days. Ridgeback Biotherapeutics developed the drug.

Final clinical data that Pfizer submitted to FDA earlier in the month showed that the pill prevented 89% of hospitalizations. Initial data indicated that Merck’s Pill was only 50% effective in preventing hospitalization. However, the FDA approved a larger trial which found it to be 30% more effective in preventing hospitalizations.

Bourla said that Paxlovid is expected to continue being highly effective in the treatment of people with the Omicron variant. This pill blocks the replication of an enzyme that is essential for virus infection. Bourla stated that it’s very hard for the virus, also known as a protease enzyme to become mutated.

Bourla said that the virus cannot create strains without this protease, during an interview for The Wall Street Journal earlier in this month. But it’s possible. It is very hard.”

On the contrary, vaccines attack the spike protein used by the virus to invade cells. The virus has gone through significant mutations during the pandemic. It has become more difficult to produce antibodies that will stop it from attaching itself to cells. There are about 30 mutations in the spike for the omicron variation.

According to South African real-world data, two-dose vaccines such as Pfizer are still very effective in preventing serious illness. The protection is significantly increased by a booster shot of Pfizer. According to data, only 33% of the two-dose initial vaccination series was effective in preventing infection. If someone is infected, the pills will help to get them under control.

The FDA’s Antimicrobial Drugs Advisory Committee narrowly endorsed Merck’s drug. It did so in a 13-to-10 vote. Although the panel was supportive of the pill, it was not without controversy. Many doctors raised concerns over potential side effects and the possible effect on future development of the virus.

Molnupirvar makes the virus mutate, and causes errors that stop it reproducing. James Hildreth CEO, Meharry Medical College Nashville, Tenn.

Hildreth stated that even though the chance of this drug causing an escape mutant, which is 1 in 10,000, 100,000 or less, it could still be very catastrophic for the entire world. This was according to the FDA panel that Hildreth spoke on November 11.

Members of the panel debated whether women who are pregnant should only take Covid in severe cases. Molnupiravir inflicted birth defects in animals. Merck didn’t intend pregnant women using the pill. They also did not use them in clinical trials.